Thomas Kelley, DO
Pulmonary Disease · Bend, ORNPI 1730293317
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,452 of the $1,621 with a category attached, or 89.5%. 10 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 26.7% of the total. Reporting peaked in 2024 at $577 and has fallen 68.0% since, to $185 in 2025.
Across 19 payments — averaging $85.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$432
- AstraZeneca$420
- Insmed, Inc.$178
- Inari Medical, Inc.$142
- Johnson & Johnson$99
- Regeneron Healthcare Solutions, Inc.$95
- plus $256 from 4 others
What the payments were for
- Food & beverage$1,45290%
- Education$17010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 4 | $432 |
| AstraZeneca | 4 | $420 |
| Insmed, Inc. | 3 | $178 |
| Inari Medical, Inc. | 1 | $142 |
| Johnson & Johnson | 1 | $99 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| United Therapeutics Corporation | 1 | $86 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Baxter Healthcare | 2 | $59 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$334
- FLOWTRIEVER CATHETER, S$142
- CT THROMBECTOMY SYSTEM KIT$142
- TAGRISSO$125
- ANDEXXA$124
- TEZSPIRE$109
How this compares
$1,621 in reported general payments places this provider in the 65th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $10,069 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $818 |
| Azithromycin | 23 | $236 |
| Prednisone | 19 | $86 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bend
- Jeremy FeldmanBend$456K
- Matthew HegewaldBend$94K
- Louis D'avignonBend$4K
- Kevin ShererBend$2K
- Gregory BlairBend$782
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.